USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth

Biochemical Pharmacology

Volumn 131, Issue , 2017, Pages 29-39

  An, Tao ^a,c   Gong, Yaxiao ^a,c   Li, Xue ^a,c   Kong, Lingmei ^a,c   Ma, Pengcheng ^b   Gong, Liang ^a,c   Zhu, Huifang ^a,c   Yu, Chunlei ^a,c   Liu, Jianmei ^a,c   Zhou, Hongyu ^a   Mao, Bingyu ^b   Li, Yan ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Colorectal cancer; USP7 inhibitor; Wnt signaling

Indexed keywords

BETA CATENIN; DEUBIQUITINASE; P 5091; PROTEIN P53; PROTEINASE INHIBITOR; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; P5091; THIOPHENE DERIVATIVE; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN; WNT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CACO-2 CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER TISSUE; CELL PROLIFERATION; COLON CARCINOMA; COLON TISSUE; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HCT 116 CELL LINE; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SW480 CELL LINE; SW620 CELL LINE; TUMOR XENOGRAFT; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HEK293 CELLS; HUMANS; PROGNOSIS; SIGNAL TRANSDUCTION; THIOPHENES; TRANSCRIPTION, GENETIC; UBIQUITIN THIOLESTERASE; UBIQUITINATION; WNT PROTEINS;

EID: 85013439611     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.02.011     Document Type: Article

References (48)

1. [1] Hershko, A., The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 12 (2005), 1191–1197.
2. [2] Nalepa, G., Rolfe, M., Harper, J.W., Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discovery 5 (2006), 596–613.
3. [3] Bedford, L., Lowe, J., Dick, L.R., Mayer, R.J., Brownell, J.E., Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discovery 10 (2011), 29–46.
4. [4] Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348 (2003), 2609–2617.
5. [5] Nicholson, B., Suresh Kumar, K.G., The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem. Biophys. 60 (2011), 61–68.
6. [6] Cummins, J.M., Rago, C., Kohli, M., Kinzler, K.W., Lengauer, C., Vogelstein, B., Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature, 428, 2004, 1 (following 486).
7. [7] Li, M., Brooks, C.L., Kon, N., Gu, W., A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13 (2004), 879–886.
8. [8] Kon, N., Zhong, J., Kobayashi, Y., Li, M., Szabolcs, M., Ludwig, T., et al. Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ. 18 (2011), 1366–1375.
9. [9] Clevers, H., Wnt/beta-catenin signaling in development and disease. Cell 127 (2006), 469–480.
10. [10] MacDonald, B.T., Tamai, K., He, X., Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17 (2009), 9–26.
11. [11] Tauriello, D.V., Maurice, M.M., The various roles of ubiquitin in Wnt pathway regulation. Cell Cycle 9 (2010), 3700–3709.
12. [12] Aberle, H., Bauer, A., Stappert, J., Kispert, A., Kemler, R., Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16 (1997), 3797–3804.
13. [13] Liu, J., Stevens, J., Rote, C.A., Yost, H.J., Hu, Y., Neufeld, K.L., et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7 (2001), 927–936.
14. [14] Chitalia, V.C., Foy, R.L., Bachschmid, M.M., Zeng, L., Panchenko, M.V., Zhou, M.I., et al. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat. Cell Biol. 10 (2008), 1208–1216.
15. [15] Chitalia, V., Shivanna, S., Martorell, J., Meyer, R., Edelman, E., Rahimi, N., C-Cbl, a ubiquitin E3 ligase that targets active beta-catenin: a novel layer of Wnt signaling regulation. J. Biol. Chem. 288 (2013), 23505–23517.
16. [16] Xue, J., Chen, Y., Wu, Y., Wang, Z., Zhou, A., Zhang, S., et al. Tumour suppressor TRIM33 targets nuclear beta-catenin degradation. Nat. Commun., 6, 2015, 6156.
17. [17] Hay-Koren, A., Caspi, M., Zilberberg, A., Rosin-Arbesfeld, R., The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin. Mol. Biol. Cell 22 (2011), 399–411.
18. [18] Shi, J., Liu, Y., Xu, X., Zhang, W., Yu, T., Jia, J., et al. Deubiquitinase USP47/UBP64E regulates beta-catenin ubiquitination and degradation and plays a positive role in Wnt signaling. Mol. Cell. Biol. 35 (2015), 3301–3311.
19. [19] Yun, S.I., Kim, H.H., Yoon, J.H., Park, W.S., Hahn, M.J., Kim, H.C., et al. Ubiquitin specific protease 4 positively regulates the WNT/beta-catenin signaling in colorectal cancer. Mol. Oncol. 9 (2015), 1834–1851.
20. [20] Ma, P., Yang, X., Kong, Q., Li, C., Yang, S., Li, Y., et al. The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of beta-catenin. Mol. Cell. Biol. 34 (2014), 4355–4366.
21. [21] Li, X.-Y., Wang, Y.-Y., Yuan, C.-M., Hao, X.-J., Li, Y., A reporter gene system for screening inhibitors of Wnt signaling pathway. Nat. Prod. Bioprospect. 3 (2013), 24–28.
22. [22] Han, L., Yue, X., Zhou, X., Lan, F.M., You, G., Zhang, W., et al. MicroRNA-21 expression is regulated by beta-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. CNS Neurosci. Ther. 18 (2012), 573–583.
23. [23] Scian, M.J., Carchman, E.H., Mohanraj, L., Stagliano, K.E., Anderson, M.A., Deb, D., et al. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 27 (2008), 2583–2593.
24. [24] Rochette, P.J., Bastien, N., Lavoie, J., Guerin, S.L., Drouin, R., SW480, a p53 double-mutant cell line retains proficiency for some p53 functions. J. Mol. Biol. 352 (2005), 44–57.
25. [25] Reyes-Zurita, F.J., Rufino-Palomares, E.E., Garcia-Salguero, L., Peragon, J., Medina, P.P., Parra, A., et al. Maslinic acid, a natural triterpene, induces a death receptor-mediated apoptotic mechanism in Caco-2 p53-deficient colon adenocarcinoma cells. PLoS ONE, 11, 2016, e0146178.
26. [26] Goswami, C.P., Nakshatri, H., PROGgeneV2: enhancements on the existing database. BMC Cancer, 14, 2014, 970.
27. [27] Weinstock, J., Wu, J., Cao, P., Kingsbury, W.D., McDermott, J.L., Kodrasov, M.P., et al. Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med. Chem. Lett. 3 (2012), 789–792.
28. [28] Chauhan, D., Tian, Z., Nicholson, B., Kumar, K.G., Zhou, B., Carrasco, R., et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22 (2012), 345–358.
29. [29] Malapelle, U., Morra, F., Ilardi, G., Visconti, R., Merolla, F., Cerrato, A., et al. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. Lung Cancer, 2016.
30. [30] Wang, Z., Vogelstein, B., Kinzler, K.W., Phosphorylation of beta-catenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. Cancer Res. 63 (2003), 5234–5235.
31. [31] Martino-Echarri, E., Henderson, B.R., Brocardo, M.G., Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget 5 (2014), 9889–9900.
32. [32] Jho, E.H., Zhang, T., Domon, C., Joo, C.K., Freund, J.N., Costantini, F., Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 22 (2002), 1172–1183.
33. [33] Herbst, A., Jurinovic, V., Krebs, S., Thieme, S.E., Blum, H., Goke, B., et al. Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics, 15, 2014, 74.
34. [34] He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 281 (1998), 1509–1512.
35. [35] Vlad, A., Rohrs, S., Klein-Hitpass, L., Muller, O., The first five years of the Wnt targetome. Cell. Signal. 20 (2008), 795–802.
36. [36] Ma, H., Nguyen, C., Lee, K.S., Kahn, M., Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24 (2005), 3619–3631.
37. [37] Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson, N.E., Poirier, G.G., Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53 (1993), 3976–3985.
38. [38] Anastas, J.N., Moon, R.T., WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13 (2013), 11–26.
39. [39] Voronkov, A., Krauss, S., Wnt/beta-catenin signaling and small molecule inhibitors. Curr. Pharm. Des. 19 (2013), 634–664.
40. [40] Oving, I.M., Clevers, H.C., Molecular causes of colon cancer. Eur. J. Clin. Invest. 32 (2002), 448–457.
41. [41] Chen, W., Chen, M., Barak, L.S., Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am. J. Physiol. Gastrointest. Liver Physiol. 299 (2010), G293–G300.
42. [42] Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461 (2009), 614–620.
43. [43] Stratford, E.W., Daffinrud, J., Munthe, E., Castro, R., Waaler, J., Krauss, S., et al. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med. 3 (2014), 36–46.
44. [44] Thorne, C.A., Hanson, A.J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C.S., et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat. Chem. Biol. 6 (2010), 829–836.
45. [45] Ohishi, K., Toume, K., Arai, M.A., Koyano, T., Kowithayakorn, T., Mizoguchi, T., et al. 9-Hydroxycanthin-6-one, a beta-carboline alkaloid from Eurycoma longifolia, is the first Wnt signal inhibitor through activation of glycogen synthase kinase 3beta without depending on casein kinase 1alpha. J. Nat. Prod. 78 (2015), 1139–1146.
46. [46] Hwang, S.Y., Deng, X., Byun, S., Lee, C., Lee, S.J., Suh, H., et al. Direct targeting of beta-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-catenin signaling. Cell Rep. 16 (2016), 28–36.
47. [47] Song, M.S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455 (2008), 813–817.
48. [48] Cai, J.B., Shi, G.M., Dong, Z.R., Ke, A.W., Ma, H.H., Gao, Q., et al. Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression. Hepatology 61 (2015), 1603–1614.